United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 38.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,125 shares of the biotechnology company’s stock after selling 1,950 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in United Therapeutics were worth $244,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. BlackRock Inc. raised its stake in United Therapeutics by 1.1% during the 1st quarter. BlackRock Inc. now owns 4,994,759 shares of the biotechnology company’s stock worth $586,236,000 after acquiring an additional 52,760 shares in the last quarter. First Trust Advisors LP raised its stake in United Therapeutics by 7.8% during the 1st quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock worth $151,477,000 after acquiring an additional 93,786 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in United Therapeutics by 2.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,982 shares of the biotechnology company’s stock worth $118,583,000 after acquiring an additional 29,427 shares in the last quarter. Geode Capital Management LLC raised its stake in United Therapeutics by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 595,615 shares of the biotechnology company’s stock worth $64,832,000 after acquiring an additional 10,863 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its stake in United Therapeutics by 26.0% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 402,159 shares of the biotechnology company’s stock worth $47,204,000 after acquiring an additional 83,037 shares in the last quarter. Hedge funds and other institutional investors own 89.17% of the company’s stock.

Several brokerages recently commented on UTHR. LADENBURG THALM/SH SH upgraded shares of United Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $103.00 to $106.00 in a research note on Thursday, August 1st. Wedbush reiterated a “buy” rating and set a $273.00 price target on shares of United Therapeutics in a research note on Thursday, August 1st. ValuEngine upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Cowen reissued a “hold” rating and set a $103.00 price objective on shares of United Therapeutics in a research report on Wednesday, May 1st. Finally, Jefferies Financial Group raised shares of United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 price objective on the stock in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. United Therapeutics presently has an average rating of “Hold” and a consensus target price of $120.36.

United Therapeutics stock traded down $2.14 during midday trading on Friday, hitting $80.71. 235,703 shares of the company’s stock were exchanged, compared to its average volume of 530,728. United Therapeutics Co. has a 12-month low of $74.31 and a 12-month high of $129.59. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.41 and a current ratio of 4.62. The stock has a market cap of $3.63 billion, a price-to-earnings ratio of 6.03 and a beta of 1.05. The firm’s 50 day simple moving average is $79.18 and its 200 day simple moving average is $96.50.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $2.26. The company had revenue of $373.60 million for the quarter, compared to the consensus estimate of $331.78 million. United Therapeutics had a negative net margin of 7.69% and a negative return on equity of 4.54%. On average, equities research analysts forecast that United Therapeutics Co. will post -1.96 EPS for the current fiscal year.

In other news, Director Raymond Dwek sold 3,750 shares of United Therapeutics stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $76.11, for a total value of $285,412.50. Following the sale, the director now owns 3,750 shares of the company’s stock, valued at $285,412.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard Giltner sold 5,000 shares of United Therapeutics stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $79.05, for a total transaction of $395,250.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at approximately $395,250. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Story: What are the advantages to having securities held in street name?

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.